(Total Views: 1094)
Posted On: 07/24/2020 3:20:54 AM
Post# of 153907
REGN-COV2: Just curious some the smarter science folks & all to weigh in how this impacts Leronlimab chances for expedited FDA approval/EUA/etc. Clearly Trump & Fauci talking REGN MABs... not Leron sadly..
Anxious for trial data to provide vindication. I believe the anecdotal evidence is strong enough to make a name for this drug based off its reputation. I’m still hopeful we will sell the full stock this year and give nice boost but prospects for future market penetration are not good if REGN ends up with a fairly decent option..?
Thinking further down the road... as this RANTES point is further explored how hard is it for big company like REGN to produce targeted products to compete w Leronlimab in other indications? I know ~6 years was quoted from NP but seems they can accelerate that greatly for big pharmas...
https://www.biopharmadive.com/news/regeneron-...al/581144/
Some takeaways:
- sophisticated production process same as Ebola
- seemingly could develop a mab for any given purpose.
- drug has clout for success vs Ebola (pending approval)
- USA has already bought near term stock!!! 300k doses
- they need stockpile, but why shop around vs scale up?**
- Beat us to south america, huge trial enrolling thousands!
- No wonder NP got the Heisman from Mexico
- Phase 3 preventative trial
There’s a lot to be positive here w Leronlimab, cancer moving forward, HIV slow but sure progress, nice boost from Covid; however, hard to take this news without seeing a big setback? Please share your thoughts. i’m all in CYDY.
How does this shake out?
Anxious for trial data to provide vindication. I believe the anecdotal evidence is strong enough to make a name for this drug based off its reputation. I’m still hopeful we will sell the full stock this year and give nice boost but prospects for future market penetration are not good if REGN ends up with a fairly decent option..?
Thinking further down the road... as this RANTES point is further explored how hard is it for big company like REGN to produce targeted products to compete w Leronlimab in other indications? I know ~6 years was quoted from NP but seems they can accelerate that greatly for big pharmas...
https://www.biopharmadive.com/news/regeneron-...al/581144/
Some takeaways:
- sophisticated production process same as Ebola
- seemingly could develop a mab for any given purpose.
- drug has clout for success vs Ebola (pending approval)
- USA has already bought near term stock!!! 300k doses
- they need stockpile, but why shop around vs scale up?**
- Beat us to south america, huge trial enrolling thousands!
- No wonder NP got the Heisman from Mexico
- Phase 3 preventative trial
There’s a lot to be positive here w Leronlimab, cancer moving forward, HIV slow but sure progress, nice boost from Covid; however, hard to take this news without seeing a big setback? Please share your thoughts. i’m all in CYDY.
How does this shake out?
(0)
(1)
